News | June 14, 2022
Nuvectis announces positive data for NXP900 in a preclinical model of Group 4 medulloblastoma
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease